These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 19616339

  • 1. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
    Manolakopoulos S, Triantos C, Theodoropoulos J, Vlachogiannakos J, Kougioumtzan A, Papatheodoridis G, Tzourmakliotis D, Karamanolis D, Burroughs AK, Archimandritis A, Raptis S, Avgerinos A.
    J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
    [Abstract] [Full Text] [Related]

  • 2. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK, HEPNET. Greece Cohort Study Group.
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [Abstract] [Full Text] [Related]

  • 3. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [Abstract] [Full Text] [Related]

  • 4. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M, Colombo M, Aroldi A, Lunghi G, Manenti E, Ponticelli C, Lampertico P.
    Antivir Ther; 2005 Nov; 10(6):709-13. PubMed ID: 16218169
    [Abstract] [Full Text] [Related]

  • 5. Portal pressure reduction after entecavir treatment in compensated HBV cirrhosis.
    Pozzi M, Pizzala DP, Maldini FF, Doretti A, Ratti L.
    Hepatogastroenterology; 2009 Nov; 56(89):231-5. PubMed ID: 19453064
    [Abstract] [Full Text] [Related]

  • 6. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B.
    Nikolaidis N, Vassiliadis T, Giouleme O, Tziomalos K, Grammatikos N, Patsiaoura K, Orfanou-Koumerkeridou E, Balaska A, Eugenidis N.
    Clin Transplant; 2005 Jun; 19(3):321-6. PubMed ID: 15877792
    [Abstract] [Full Text] [Related]

  • 7. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN, Asia Hepatitis Lamivudine Study Group.
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [Abstract] [Full Text] [Related]

  • 8. The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis.
    Kilic ZM, Kuran S, Akdogan M, Cicek B, Oguz D, Odemis B, Sasmaz N.
    Adv Ther; 2008 Mar; 25(3):190-200. PubMed ID: 18385953
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma.
    Kim JH, Park JW, Koh DW, Lee WJ, Kim CM.
    Liver Int; 2009 Feb; 29(2):203-7. PubMed ID: 18662281
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL.
    Antivir Ther; 2008 Feb; 13(4):571-9. PubMed ID: 18672536
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.